PFE PFIZER INC
Company Analysis
Latest News
Pfizer Reaffirms Full-Year 2026 Financial Guidance Amid CFO Transition
Pfizer has reaffirmed its full-year 2026 financial guidance, which was originally introduced on December 16, 2025. The company confirmed its outlook following...
🔴 Pfizer Inc is trading 2.8% down today after CFO departure news
Pfizer Inc is trading at $25.20 (-2.76%) following the announcement that Chief Financial Officer Dave Denton will step down on August 15, 2026. • The company...
Pfizer CFO Dave Denton to Depart; Cecile Guegan Appointed Interim CFO
Pfizer announced that Chief Financial Officer Dave Denton will step down from his role, effective August 15, 2026, to pursue an opportunity outside the...
Pfizer Advances Monthly Obesity Shot, Reporting 15.9% Weight Loss in Trial
Pfizer reported positive Phase 2b study results for berobenatide, an investigational once-monthly weight loss injection. Data presented at the American...
Pfizer’s Braftovi Slashes Cancer Progression Risk by 56% in Phase 3 Trial
Pfizer announced Phase 3 BREAKWATER trial results for BRAFTOVI (encorafenib) at the 2026 ASCO Annual Meeting. The study evaluated the drug combination in...
Pfizer Advances in Obesity Race with New Late-Stage Trial for Monthly Drug
Pfizer launched the VESPER-6 Phase 3 clinical trial for its weight-loss drug candidate, berobenatide. The study evaluates the safety and efficacy of a...
Pfizer cuts prostate cancer progression risk 52%, targeting specific gene mutations
Pfizer reported Phase 3 TALAPRO-3 study results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated a combination of...
Pfizer and Innovent partner on 12 cancer drugs in major global deal
Pfizer and Innovent Biologics have formed a global strategic collaboration to develop 12 early-stage cancer medicines. The partnership focuses on antibody-drug...
Pfizer and Partners Receive Positive EU CHMP Opinion for PADCEV Combination
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approving PADCEV in combination with Merck's Keytruda. The regimen...
Pfizer Advances 25-Valent Pediatric Pneumococcal Vaccine to Phase 3 After Strong Phase 2 Data
Pfizer announced that its investigational 25-valent pneumococcal conjugate vaccine (25vPnC) showed up to 15-fold higher antibody responses compared to Prevnar...
Pfizer, Other Pharma Stocks, Dip on Planned Expansion of Trump's Discounted Drug Program
Shares of Pfizer, Eli Lilly, and Novo Nordisk fell on Monday, May 18, 2026. The decline follows reports of an expected expansion of the TrumpRx discounted...
Pfizer Licenses Breast Cancer Drug VEPPANU to Rigel in $405M Deal
Pfizer and Arvinas granted Rigel Pharmaceuticals exclusive global rights to the recently approved breast cancer drug VEPPANU (vepdegestrant). Rigel will manage...
Pfizer's Dividend Sustainability Questioned After Q1 Net Income Drop
A May 12, 2026, analysis scrutinizes Pfizer's dividend yield. The yield currently stands at 6.7%. The review follows the first-quarter earnings report. Net...
Pfizer and hVIVO Report Positive Efficacy for mRNA Influenza Vaccine in Human Challenge Trial
An hVIVO and Pfizer-funded human challenge trial showed high efficacy for a nucleoside-modified messenger ribonucleic acid (modRNA) influenza vaccine. The...
Pfizer defends 6.5% dividend, citing strong Q1 results and legal wins
Pfizer CEO Albert Bourla and CFO David Denton reaffirmed their commitment to the company's 6.5% dividend yield on May 7, 2026. The company's Q1 earnings report...
Pfizer's first quarter 2026 revenue of $14.5B beats estimates, driven by 22% growth in new and acquired products.
Pfizer reported first-quarter 2026 revenues of $14.5 billion, representing 2% year-over-year operational growth, and an adjusted diluted EPS of $0.75. The...
Pfizer Inc Q1 2026 Earnings Preview: What Analysts Expect on May 05, 2026
For the first quarter of 2026, analysts anticipate Pfizer will report a consensus revenue of $13.82 billion and adjusted EPS of $0.74, while the stock...
Trump Imposes 100% Pharma Tariffs and Fires Attorney General, Seeking Lower Prices
The Trump administration announced tariffs of up to 100% on imported branded drugs and active ingredients. This policy aims to pressure pharmaceutical...